THU0552 Haplotypes of Vitamin D Receptor Gene: Both Risky and Protective for Fibromiyalgia (FMS): Table 1.

Abstract

BackgroundClinical observations suggest that vitamin D may influence fibromyalgia etiology. FMS and vitamin D deficiency share a similar symptom profile; the relationship between these conditions is unclear. Vitamin D receptor is a crucial mediator of the symptoms of vitamin D deficiency. Thus, vitamin D receptor gene polymorphisms or haplotypes may contribute to vitamin D resistance.ObjectivesThis study evaluated the clinical relationship between FMS and vitamin D gene among Turkish FMS patients.Methods73 patients with FMS were diagnosed according to the ACR 2010 criteria; the control group included 61 healthy unrelated volunteers. The rs2228570 (Fok I), rs1544410 (Bsm I), rs7975232 (Apa I) and (rs731236) Taq I polymorphisms were examined using PCR-RFLP.ResultsIn individual SNP analyses, none of the snps have been found to be associated with FMS (p values are 0.491, 0.477, 0.207, and 0.736 respectively). However, it has been detected that there is a strong association between haplotypes of VDR gene polymorphisms and FMS. As a result of this study, the effect of haplotypes is shown to be both risky and protective. P value of risk haplotypes ATC (rs2228570, rs1544410, rs7975232) is 0,015 (26,5%) and TTT is 0,0068 (12,8%). The p value of collected risk haplotypes (ATC, TTT) is 0,006 (39,3%) and (ATC, TGT, and TTT) 0,000009 (58,7%). Frequent protective haplotype TTC is 0,0385 (6,8%). The p value of collected protective haplotypes (ATT, TCG, and TTC) is 0,008 (38%).Table 1.Haplotype analysis of VDR gene polymoprhisms (1 = Bsm1, 2 = Fok1, 3 = Taq1)Haplo No.HaplotypeControlCasePORRRRisk/ProtectiveBsm1-Apa1-Fok1(%)(%)(95% CI)(95% CI)1ATT31.738.40.3270.740.83R(1.33–0.42)(1.21–0.56)2ATC26.514.50.0152.372.01P(4.82–1.17)(3.59–1.13)3TGT19.410.50.0772.051.85P(4.61–0.91)(3.71–0.92)4TTT12.82.60.00685.504.92P(21.52–1.41)(18.4–1.34)5TGC5.212.30.0750.390.39R(1.14–0.13)(1.13–0.16)6TTC1.16.80.03850.150.16R(1.17–0.02)(1.19–0.02)2+4ATC+TTT39.317.10.0063.12.28P(5.99–1.61)(3.73–1.39)2+3+4ATC+TGT+TTT58.727.60.0000093.732.13P(6.74–2.06)(3.04–1.49)1+5+6ATT+TGC+TTC3857.50.00080.390.60R(0.68–0.22)(0.82–0.44)ConclusionsThe present study is the first study evaluating VDR gene in patients with FMS. Our results suggest that haplotypes in VDR are strongly associated with fibromyalgia expressing both risk and protective effect. Our findings may help guide future research needed to define the role of vitamin D in FMS.Disclosure of InterestNone declared

Psychological Outcomes and Quality of Life of Fibromyalgia Patients with Vitamin D Supplementation—A Meta-Analysis

“…Eligible studies had to meet the following criteria: (a) randomized controlled trials or prospective cohort studies; (b) enrollment of fibromyalgia patients who received vitamin D supplementation; (c) reporting of psychological outcomes and quality of life, measured by the 36-item Short Form Health Survey (SF-36), FIQ, Beck Depression Inventory (BDI), VAS, Widespread pain index (WPI), or Pittsburgh Sleep Quality Index (PSQI); and (d) published in English or Chinese. Articles reporting a case or series of cases, review articles, animal studies, conference abstracts, editorials, and letters were excluded ( Supplementary Table S2 , [ 4 , 5 , 7 , 10 , 14 , 18 , 25 , 29 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 ,…”

“…Table S2: Reasons for exclusion of the articles. References [ 4 , 5 , 7 , 10 , 14 , 18 , 25 , 29 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 ,…”

A Comprehensive Review of the Genetic and Epigenetic Contributions to the Development of Fibromyalgia

“…This study protocol followed the methodology described in the PRISMA statement for systematic reviews [ 17 ]. A comprehensive search of several databases was performed on 4 September 2022.…”

“…Specifically, women with the C allele for Apal polymorphism are 3.33 times more likely to have FM, and women with the T allele for Fokl polymorphism are 10.9 times more likely to have FM. Further, Balkarli et al showed that haplotypes of VDR gene polymorphisms are risky (ATC and TTT) and protective (TTC) for FM [ 17 ]. In addition, cannabinoid receptors in the body are implicated in the mood symptoms of FM.…”